Publications by authors named "Hajar Mehr Azin"
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial.
Akram Ansarifar Ramin Hamidi Farahani Ahmad Karimi Rahjerdi Mohammadreza Ahi Ali Sheidaei Hajar Mehr Azin
Vaccine X
December 2023
Background: The FAKHRAVAC®, an inactivated SARS-CoV-2 vaccine, was assessed for safety and immunogenicity.
Methods And Findings: In this double-blind, placebo-controlled, phase I trial, we randomly assigned 135 healthy adults between 18 and 55 to receive vaccine strengths of 5 or 10 μg/dose or placebo (adjuvant only) in 0-14 or 0-21 schedules. This trial was conducted in a single center in a community setting.
Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
Fatemeh Gholami Ramin Hamidi Farahani Ahmad Karimi Rahjerdi Mohammadreza Ahi Ali Sheidaei Hajar Mehr Azin
BMC Infect Dis
February 2023
Article Synopsis
- * In the trial, 500 participants were divided into two groups, receiving either the vaccine or a placebo, and their immune responses and side effects were monitored for up to six months.
- * Results showed that the vaccine significantly increased neutralizing antibody levels compared to the placebo, with common side effects being mild and primarily involving tender injections and headaches, indicating the vaccine's safety and effectiveness.